2022
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
Li C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.Peer-Reviewed Original ResearchMetastatic colorectal cancerExperimental armColorectal cancerMetastatic colorectal cancer (mCRC) trialsMetastatic colorectal cancer patientsPhase Ib/IITrial dataHistorical trial dataColorectal cancer trialsDisease control rateObjective response ratePhase 3 trialProgression-free survivalColorectal cancer patientsStandardized mortality ratioEarly phase trialsEarly phase clinical developmentLogistic regression modelsMultiple experimental armsPrimary endpointOverall survivalPrior linesEfficacy signalsSafety profileCombination therapyIntegrated approach to collecting patient reported toxicities in a colorectal cancer trial.
Gaddy J, Sanoff H, Deal A, Basch E, Wood W. Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Journal Of Clinical Oncology 2022, 40: 51-51. DOI: 10.1200/jco.2022.40.4_suppl.051.Peer-Reviewed Original ResearchDose decreaseSevere symptomsToxicity ratesSevere toxicityClinical trialsGenotype-guided dosing strategyAppropriate dose modificationPRO-CTCAEStandard drug dosesAdverse event assessmentMulti-center clinical trialClinically relevant issuesColorectal cancer trialsHematologic toxicityMCRC patientsDose modificationAbdominal painAdvanced CRCToxicity gradeCycling patientsClinical characteristicsDosing strategiesAdverse eventsDrug doseClinician grading
2013
Cancer clinical trial accessibility in the United States: An analysis of travel distance.
Latif A, Stensland K, Hendricks R, Moshier E, Godbold J, Oh W, Galsky M. Cancer clinical trial accessibility in the United States: An analysis of travel distance. Journal Of Clinical Oncology 2013, 31: 6540-6540. DOI: 10.1200/jco.2013.31.15_suppl.6540.Peer-Reviewed Original ResearchTumor typesCancer trialsFirst-line metastatic diseaseNearest clinical trial siteSolid tumor typesBreast cancer trialsCancer clinical trial enrollmentClinical trial enrollmentProstate cancer trialsLung cancer trialsColorectal cancer trialsTherapeutic intervention trialsClinical trial accessMetastatic diseaseClinical trial sitesSolid tumorsClinical trialsCancer clinical trialsTrial enrollmentInclusion criteriaTumorIntervention trialsZip-codeTrial accessTrials
2004
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy VH, Krumholz HM, Gross CP. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. JAMA 2004, 291: 2720-2726. PMID: 15187053, DOI: 10.1001/jama.291.22.2720.Peer-Reviewed Original ResearchConceptsCancer trialsCancer clinical trialsClinical trialsTrial participantsEnrollment fractionWhite patientsAge groupsCross-sectional population-based analysisProstate cancer clinical trialsCancer research participationCancer trial participantsColorectal cancer trialsPatients 75 yearsIncident cancer patientsLung cancer trialsPopulation-based analysisRelative risk ratiosAge-based disparitiesYears of ageNational Cancer InstituteLogistic regression modelsLittle recent informationTrial enrolleesYounger patientsPatient group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply